Scientific programme

The plenary lectures by renowned invited speakers will provide updates on the main topics of the meeting and showcase some of the latest clinical and basic science.

State-of-the-art lectures by renowned scientists will provide the best available level of knowledge in the field of Thrombosis and Haemostasis at present.

Confirmed speakers:

Manuela Albisetti | Oral Anticoagulants in Children: Current Evidence and Practical Challenges
Sonja Alesci | Contemporary Management of von Willebrand Disease: Insights from the New Guideline
Harriet E. Allan | Mitochondrial effector functions of platelets
Muhammad Arshad | Molecular Pathways Linking von Willebrand Factor and EC permeability
Matthew Auton | VWF basic research
Cihan Ay | FXI and FXII Inhibition as Antithrombotic Therapy: Hype, Hope, and Hard Lessons
Lennart Beckmann | CAR-T cell therapy associated thrombosis and bleeding
Ingvild Birschmann | Aggregometry – strengths and limitations
Jan Blatny | Beyond Factor Replacement: The Continuing Relevance of Inhibitors in Pediatric Hemophilia
Roza Chaireti | Risk stratification according to genotype and effect of thromboprophylaxis on obstetric outcomes in women with antithrombin deficiency
Jeroen Eikenboom | Precision Medicine in von Willebrand Disease: The Emerging Role of siRNA Therapeutics
Cornelia Englisch | Clonal hematopoiesis and thrombosis risk: current research and clinical gaps
Dietmar Fries | New anticoagulation strategies—which ones could make sense in routine clinical practice?
Vasiliki Gkalea | Monoclonal gammopathy of bleeding and thrombotic significance
Claudine Graf | Coagulation Meets Immunity: How Hemostasis Shapes Anti-Tumour Responses
Roberta Gualtierotti | Muscle haemorrhages in patients with bleeding disorders – Diagnostic and therapy
Christina Hart | Prophylaxis and treatment of pregnancy-associated thrombosis
Wolf Hassenpflug | Prophylaxis in Paediatric von Willebrand Disease: Current Practice and Future Directions
Lars Heubner | Guideline-compliant anticoagulation in critically ill patients
Thomas Hilberg | Muscle function in people with bleeding disorders
Katharina Holstein | Bleeding Phenotypes and Treatment Indications in Rare Coagulation Factor Deficiencies
Aydin Husenyov | Treatment of patients with cardiac thrombosis
Abishek Jain | Music-inspired perfusion technology for vessel-on-a-chip systems
Kerstin Jurk | Kinase signalling in platelets
Alexandre Kauskot | The role of F-actin disassembly in mechano-dependent VWF-GPIbα interaction
Robert Klamroth | Non-Factor-Therapies in Haemophilia
Ralf Knöfler | When Bruising is more than Bruising
Rory Koenen | Platelet-derived extracellular vesicles: therapeutic targets in cardiovascular diseases
Shrey Kohli | Preeclampsia – Role of angiogenesis and thromboinflammation
Christoph Königs | Modern Haemophilia Care in Children: Beyond Factor Replacement
Oliver Königsbrügge | Anticoagulation in patients with chronic kidney disease
Maria Korte | The Added Value of Genetics in Bleeding Disorders – Lessons from Clinical Cases
Ina Kötter | The Changing Landscape of Vasculitis
Johanna Kremer Hovinga | Congenital TTP Across the Lifespan: Crises, Treatment and Follow-Up of Heterozygous Carriers
Sebastien Lacroix-Desmazes | Inhibitors in Hemophilia in the era of long-acting factors and non-factor therapies – nothing to see here?
Florian Langer | Bleeding in Amyloidosis
Riitta Lassila | Role of red blood cells in bleeding
Matthias Laudes | GLP-1 agonists in the treatment of obesity – Efficacy and safety in patients with arterial and venous thromboembolism
Edelgard Lindhoff-Last | Superficial Venous Thrombosis – Beyond a Benign Condition
Beate Luxembourg | Do genetics aid in clinical decision making for Antiphrombin
Blandine Maitre | New insights in platelet senescence
Christoph Male | Anticoagulation management in children and adolescents
Martin Olivieri | Rare Bleeding Disorders in Childhood: Diagnostic and Therapeutic Challenge
Behnaz Pezeshkpoor | From genotype to clinical decision making in platelet bleeding disorders
Mirko Pinotti | Gene Editing for Hemophilia
Anna Randi | Angiopoietin Signalling in von Willebrand Disease: New Insights into Vascular Biology
Ulrich Sachs | Diagnosis and management of antiphospholipid syndrome
Ulrich Sachs | How can laboratory tests help confirm a diagnosis of ITP?
Felix Schmitt | Why do we need to assess post-operative bleeding compliactions differently than in the operating room?
Ingmar Schön | Platelet Mechanosensing: How Physical Forces Shape Haemostasis
Linda Schönborn | Thrombotic risk of platelet factor 4-dependent platelet-activating antibodies
Heike Singer | Mapping and modulating endogenous F8 expression using patient-specific iPSC-Derived LSEC Models
Frauke Swieringa | Platelet function under flow: microfluidics and shear-based assays
Sophie Susen | The Thrombosis–Bleeding Dilemma in LVAD and ECMO
Jecko Thachil | Von Willebrand Disease: The Hidden Burden Beyond Bleeding
Johannes Thaler | Body Fluids and Haemostasis: Emerging Concepts and Clinical Relevance
Andreas Tiede | Treating acquired Haemophilia A: Current Challenges and Future Directions
Merel Timmer | Muscle haemorrhages in patients with bleeding disorders – Rehabilitation
Fabian Tomschi | Fall risks in patients with bleeding disorders
Karoline Trautmann-Grill | Understanding Immune Thrombocytopenia Beyond the Platelet Count
Rolf Urbanus | Prophylactic treatment of inherited platelet disorders
Charis von Auer | Guideline-Based Diagnosis and Management of Thrombotic Thrombocytopenic Purpura
Karen Vanhoorelbeke | A novel CAR-T cell therapy for TTP
Yuanyuan Wang | Von Willebrand Factor Under Flow: A Vascular Bridge Between Endothelial Activation, Thrombosis, and Metastasis
Rebekka Wiedenhöfer | Platelet-Type von Willebrand Disease: From Diagnosis to Patient Management
Jochen Wilhelm | VWF Multimer Analysis Across Platforms: Strengths, Pitfalls, and Diagnostic Impact
Carlo Zaninetti | Visualising Platelet Abnormalities by Immunofluorescence and Advanced Imaging
Barbara Zieger | Hereditary disorders of platelet function and number

Selected oral presentations on the latest findings from basic and clinical research.

Communicate visually the quintessence of your work by presenting complex information clearly and concisely. Additionally, you have the opportunity to network by discussing with peers and experts.

These sessions are led by recognized authorities in their fields. After a presentation about their specialised topic the experts will open the session for discussion, which will be driven by active audience participation.

Symposia will be company-organised sessions including academic presentations and roundtable discussions on the latest scientific, diagnostic, and therapeutic advances in the field of thrombosis and haemostasis.

Pipeline sessions are novel session format. Companies will highlight their latest product developments in the field of thrombosis and haemostasis during 15-minute presentations.